title: Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells.
abstract: Multiple myeloma is a monoclonal postgerminal center tumor that has phenotypic features of plasmablasts and/or plasma cells and usually localizes at multiple sites in the bone marrow. The pathogenesis of multiple myeloma is complex and dependent on the interactions between tumor cells and their microenvironment. Different cytokines, chemokines, and proangiogenic factors released in the tumor microenvironment are known to promote multiple myeloma cell growth. Here, we report recent advances on the role of 2 strictly related immunomodulatory cytokines, interleukin-27 (IL-27) and IL-23, in human normal and neoplastic plasma cells, highlighting their ability to (i) act directly against multiple myeloma cells, (ii) influence the multiple myeloma microenvironment by targeting osteoclast and osteoblast cells, and (iii) modulate normal plasma cell function. Finally, the therapeutic implication of these studies is discussed.
authors: Hematology and Blood and Marrow Transplantation (BMT) Center, University of Parma, Parma, Italy.
authors: Nicola
authors: N
authors: Giuliani
authors: Irma
authors: I
authors: Airoldi
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D020381:Interleukin-17 / Q000494:pharmacology / Q000627:therapeutic use*; D053759:Interleukin-23 / Q000494:pharmacology / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy*; D010006:Osteoblasts / Q000187:drug effects; D010950:Plasma Cells / Q000187:drug effects*; D058504:Th17 Cells / Q000187:drug effects; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D020381:Interleukin-17; D053759:Interleukin-23